Analysis of Selected Serum Cytokines to Evaluate the Early Efficacy of Benralizumab, Dupilumab, and Mepolizumab in Severe Eosinophilic Asthma Treatment.

Int J Mol Sci · 2025 · PMC12563325 · PMID 41155381

Europe PMC DOI

hedged sentence

0.0590

closest p · 1.2× alpha

0.0590

boldest claim

The sentences

near-significantp = 0.059so close (0.05 < p ≤ 0.1)

Dup: p = 0.045), with dupilumab achieving a near-significant reduction (median −0.7 pg/mL, 95% CI: −1.5, 0.0, p = 0.059).

also in 821 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.